CYT387, a Novel JAK2 Inhibitor, Suppresses IL-13-Induced Epidermal Barrier Dysfunction Via miR-143 Targeting IL-13Rα1 and STAT3
Authors:
- 15 November 2020
- journal article
- research article
- Published by Springer Nature in Biochemical Genetics
- Vol. 59 (2) , 531-546
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease influencing not only children but also adults. It is well-known that AD has a complex pathogenesis without effective therapy. Herein, we explored the function and mechanism of CYT387, a novel JAK2 inhibitor, on epidermal barrier damage. HaCaT cells exposed with high-concentration Ca2+ (1.8 mM) for 14 days were recruited for the model of keratinocytes (KC). The cell model of skin barrier damage was induced by IL-13, and KC markers such as filaggrin (FLG), loricrin (LOR), and involucrin (IVL) were detected to judge the success of the model. In this study, we found that miR-143 was lowly expressed whereas IL-13Rα1 was highly expressed in blood cells of patients with AD, indicating their negative correlation. Moreover, IL-13 treatment down-regulated miR-143 and up-regulated activated JAK2 and STAT3 phosphorylation, which was reversed by CYT387 administration. The dual-luciferase reporter assay verified that miR-143 could directly bind to 3′-UTR of IL-13Rα1, as well as STAT3. Furthermore, the function of CYT387 in the skin barrier damage induced by IL-13 was abolished by miR-143 inhibitor. Thus, CYT387 might alleviate IL-13-induced epidermal barrier damage via targeting IL-13Rα1 and STAT3 by miR-143 to repress inflammation. These findings revealed that the protective effects and the underlying mechanisms of CYT387 in AD, which provided evidence that miR-143 may be a novel therapeutic target for AD.Keywords
This publication has 29 references indexed in Scilit:
- Filaggrin silencing by shRNA directly impairs the skin barrier function of normal human epidermal keratinocytes and then induces an immune responseBrazilian Journal of Medical and Biological Research, 2015
- Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 2014
- Lessons from miR-143/145: the importance of cell-type localization of miRNAsNucleic Acids Research, 2014
- MicroRNA-143 Downregulates Interleukin-13 Receptor Alpha1 in Human Mast CellsInternational Journal of Molecular Sciences, 2013
- Pathomechanism of atopic dermatitis in the perspective of T cell subsets and skin barrier functions – “Which comes first, the chicken or the egg?”Dermatologica Sinica, 2012
- Microarray Analysis of Differentially Expressed microRNAs in Allergic RhinitisAmerican Journal of Rhinology & Allergy, 2011
- Transcriptional regulation by STAT6Immunologic Research, 2011
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasmsBlood, 2010
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsLeukemia, 2009
- Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6Clinical Immunology, 2008